Roger Pomerantz was formerly Worldwide Head of Licensing & Acquisitions, Senior Vice President at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals and academic alliances. Previously, he served as Senior Vice President and Global Franchise Head of Infectious Diseases at Merck. Prior to joining Merck, Roger was Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. He joined Johnson & Johnson in 2005 as President of Tibotec Pharmaceuticals, Inc. Previously, Roger received his B.A. in Biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his Internal Medicine internship and residency training, and his subspecialty clinical and research training in Infectious Diseases and Virology at the Massachusetts General Hospital (M.G.H.) of the Harvard Medical School and was selected and served as the Chief Medical Resident at M.G.H. His post-doctoral research training in Molecular Retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology, in the laboratory of Nobel Laureate, Dr. David Baltimore. Subsequently, Roger was Professor of Medicine, Biochemistry and Molecular Pharmacology, Chief of Infectious Diseases, and the Founding Director and Chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School. He has developed seven approved infectious disease drugs in important diseases including HIV, HCV, and tuberculosis.
Co-founder Seres Health, Managing Partner and CEO, Flagship Ventures
Noubar Afeyan is Managing Partner and CEO of Flagship Ventures, an early-stage venture firm. He is a recognized technologist and entrepreneur. During his 25-year career as inventor, entrepreneur, CEO and venture capitalist, Noubar has co-founded and helped build 26 successful life science and technology startups. He was founder and CEO of PerSeptive Biosystems, a leader in the bio-instrumentation field that grew to over $100M in annual sales within six years from its first sales. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he was Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics. Currently Noubar serves on a number of public and private company boards including Affinnova, BIND Therapeutics, BG Medicine, Eleven Biotherapeutics, Pronutria, Joule Unlimited and Moderna Therapeutics. Previously, he was a member of the founding team, director and investor in several highly successful ventures including Chemgenics Pharmaceuticals (acquired by Millennium Pharmaceuticals), Color Kinetics (acquired by Philips), and Adnexus Therapeutics (acquired by Bristol-Myers Squibb). He earned his Ph.D. in Biochemical Engineering from MIT in 1987.
Chief Executive Officer, Co-founder Seres Health, Partner, Flagship Ventures
David Berry joined Flagship in 2005 where he focuses on innovating, entrepreneuring, and investing in new ventures in life sciences and sustainability. He is a founder of Flagship portfolio companies LS9, Joule Unlimited, Eleven Biotherapeutics, Seres Health, Pronutria, among others. David was founding CEO of Joule and Pronutria. He was also a Board member of Flagship portfolio company CGI Pharmaceuticals (acquired by Gilead in 2010), and currently serves on the boards of Joule, Eleven, Seres and Pronutria. David previously completed his combined MD-PhD from Harvard Medical School and the MIT Biological Engineering Division in just over 5 years. He has been recognized with over 50 awards and honors as an innovator including receiving the prestigious Lemelson-MIT Student Prize for invention and innovation, being named the Innovator of the Year by Technology Review, and being selected by the US State Department as 1 of 12 Innovators Helping to Reshape Realty. He also speaks across the globe on topics including innovation, sustainability, biotechnology, and entrepreneurship, including at the National Academies, for the Prince of Girona Foundation, and at Google Solve for X. David previously served on the MIT Corporation, its Board of Trustees, and currently serves on the boards of multiple not-for-profits in education and the arts, and has been appointed to the United Nations Sustainable Development Solution Network Leadership Council.
President and CEO, Selecta Biosciences
Werner Cautreels is President and CEO of Selecta Biosciences and was previously CEO of Solvay Pharmaceuticals, the pharmaceuticals division of the Solvay Group (Brussels, Belgium) until Solvay Pharmaceuticals was acquired by Abbott Laboratories. Before becoming the CEO of Solvay Pharmaceuticals, Werner was their Global Head of R&D. Prior to joining Solvay, he was employed by Sanofi, Sterling-Winthrop, and Nycomed-Amersham in a variety of R&D management positions in Europe and in the United States. He was a director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, MA, USA) from 1999-2006. He is currently a director of Selecta and Galapagos NV (Mechelen, Belgium). He was the President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. He was born in Antwerp, Belgium, and graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He received his management education from the Harvard Business School.
Senior Counsel, Covington & Burling, LLP
Peter Hutt is a senior counsel in the Washington, D.C. law firm of Covington & Burling specializing in food and drug law. Peter served as Chief Counsel for the Food and Drug Administration during 1971-1975. He is the co-author of the casebook used to teach food and drug law throughout the country. He has been a member of the Institute of Medicine since it was founded in 1971, and he currently serves on the Panel on the Administrative Restructuring of the National Institutes of Health. He also serves on academic and venture capital advisory boards, and the boards of numerous startup biotechnology companies. He was named by The Washingtonian magazine as one of Washington’s 50 best lawyers (out of more than 40,000) and as one of Washington’s 100 most influential people; by the National Law Journal as one of the 40 best health care lawyers in the United States; and by European Counsel as the best FDA regulatory specialist in Washington, D.C.